NCT03947346Completed
Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
Source: ClinicalTrials.gov · Last updated 17 Jul 2025
Brief summary (registry, in English)
The main purpose of this study is to learn more about biomarkers of kidney function in the blood and urine of neuroblastoma survivors. A biomarker is a biological molecule found in blood, urine, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 28 (actual)
- First submitted
- 9 May 2019
- Start date
- 9 May 2019
- Primary completion date
- 15 Jul 2025
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Neuroblastoma
- NCT number
- NCT03947346
What you commit to
- Study type: Observational
- Participants enrolled: 28
- From 9 May 2019 to the primary completion date, 15 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated with observation only
Other illness
- Patients with multiple primary cancers
Who the study is looking for
- Diagnosis of neuroblastoma between 0-18 years of age
- \< 21 years of age at time of study enrollment
- Two or more years from completion of systemic chemotherapy and/or radiation therapy
Age in the registry: - to 20 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.